Sign In
Buy PAVM
$4.68
-0.230 (-4.68%)
At Close: Jun 23, 2026
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
08:15am, Monday, 18'th Nov 2024
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript
03:49pm, Thursday, 14'th Nov 2024
PAVmed Inc. (NASDAQ:PAVM ) Q3 2024 Earnings Call Transcript November 14, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conferenc
PAVmed Provides Business Update and Third Quarter 2024 Financial Results
08:01am, Thursday, 14'th Nov 2024
Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
08:01am, Wednesday, 13'th Nov 2024
EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue
Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
08:01am, Tuesday, 05'th Nov 2024
Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets NEW YORK
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
08:31am, Thursday, 31'st Oct 2024
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 31, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical tec
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
08:31am, Wednesday, 30'th Oct 2024
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , Oct. 30, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention me
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
07:51am, Tuesday, 15'th Oct 2024
Patent covers proprietary method using methylation of the CCNA1 gene to help detect esophageal precancer and cancer NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
07:51am, Thursday, 10'th Oct 2024
Grant will fund research to optimize Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center NEW YORK , Oct. 10, 2024 /PRNewswire/ -- PAVmed
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
08:01am, Wednesday, 09'th Oct 2024
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
07:49am, Tuesday, 08'th Oct 2024
Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a com
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
08:01am, Tuesday, 24'th Sep 2024
Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a c
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
04:30pm, Monday, 16'th Sep 2024
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK , Sept.
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK , Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD
